AstraZeneca's Enhertu Receives EU Approval as First Tumour-Agnostic HER2-Directed Therapy
AZN sits 40% above its 52-week low of $134.9.
Summary
AstraZeneca's Enhertu has received EU approval as the first tumour-agnostic HER2-directed therapy for previously treated HER2-positive metastatic solid tumours, expanding its market significantly.
Key Events · Product Development and Regulatory · AZN
-
EU Approval for Enhertu
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior treatment and have no satisfactory treatment options.
-
First Tumour-Agnostic HER2-Directed Therapy
This marks Enhertu as the first tumour-agnostic HER2-directed therapy and antibody drug conjugate approved in the EU, allowing treatment for HER2-positive cancers regardless of their origin.
-
Broad Patient Population
The approval is based on positive Phase II trial results (DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02) demonstrating clinically meaningful responses across various tumour types, addressing a significant unmet need.
-
Milestone Payment Triggered
Following this approval, AstraZeneca will make a $25 million milestone payment to Daiichi Sankyo for the tumour-agnostic indication.
Analysis · AZN · Life Sciences
This approval significantly expands the market for Enhertu in the European Union, allowing it to treat HER2-positive solid tumours regardless of their origin. As the first tumour-agnostic HER2-directed therapy in the EU, it addresses a broad unmet medical need for patients with previously treated metastatic cancers, potentially driving substantial revenue growth for the drug.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 39.1% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $188.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $292.2B. The 52-week trading range was $134.90 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.